Y
Yasuo Ohashi
Researcher at RMIT University
Publications - 118
Citations - 7818
Yasuo Ohashi is an academic researcher from RMIT University. The author has contributed to research in topics: Cancer & Randomized controlled trial. The author has an hindex of 33, co-authored 118 publications receiving 7320 citations. Previous affiliations of Yasuo Ohashi include University of Tokyo & Chuo University.
Papers
More filters
Journal ArticleDOI
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto,M. Sasako,Toshiharu Yamaguchi,Taira Kinoshita,Masashi Fujii,Atsushi Nashimoto,Hiroshi Furukawa,Toshifusa Nakajima,Yasuo Ohashi,Hiroshi Imamura,Masayuki Higashino,Yoshitaka Yamamura,Akira Kurita,Kuniyoshi Arai +13 more
TL;DR: S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer and has a higher rate of overall survival than the surgery-only group.
Journal ArticleDOI
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
Tadatoshi Takayama,Teruaki Sekine,Masatoshi Makuuchi,Susumu Yamasaki,Tomoo Kosuge,Junji Yamamoto,K Shimada,Michiie Sakamoto,Setsuo Hirohashi,Yasuo Ohashi,Tadao Kakizoe +10 more
TL;DR: Adoptive immunotherapy is a safe, feasible treatment that can lower recurrence and improve recurrence-free outcomes after surgery for HCC.
Journal ArticleDOI
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis
Gastric (Global Advanced),Xavier Paoletti,Koji Oba,Tomasz Burzykowski,Stefan Michiels,Yasuo Ohashi,Jean-Pierre Pignon,Philippe Rougier,Junichi Sakamoto,Daniel J. Sargent,Mitsuru Sasako,Eric Van Cutsem,Marc Buyse +12 more
TL;DR: Among the RCTs included, postoperative adjuvant chemotherapy based on fluorouracil regimens was associated with reduced risk of death in gastric cancer compared with surgery alone.
Journal ArticleDOI
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Yuichiro Ohe,Yasuo Ohashi,Kaoru Kubota,Tomohide Tamura,Kazuhiko Nakagawa,S. Negoro,Yutaka Nishiwaki,Nagahiro Saijo,Yutaka Ariyoshi,Masahiro Fukuoka +9 more
TL;DR: Four platinum-based combination regimens against cisplatin plus irinotecan have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.
Journal ArticleDOI
Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis
Yasutoshi Muto,Shunichi Sato,Akiharu Watanabe,Hisataka Moriwaki,Kazuyuki Suzuki,Akinobu Kato,Masahiko Kato,Teiji Nakamura,Kiyohiro Higuchi,Shuhei Nishiguchi,Hiromitsu Kumada,Yasuo Ohashi +11 more
TL;DR: Oral supplemental treatment with BCAA may reduce the risk of liver cancer in cirrhotic patients with these specific factors, and when the BCAA group and the diet group were compared for factors that interacted with the treatment arms, the risk for liver cancer was significantly reduced.